Overview
flowchart TD
companies_neuron23["Neuron23 Inc."]
style companies_neuron23 fill:#4fc3f7,stroke:#333,color:#000
companies_neuron23_0["Leadership"]
companies_neuron23 -->|"includes"| companies_neuron23_0
style companies_neuron23_0 fill:#81c784,stroke:#333,color:#000
companies_neuron23_1["Focus Areas"]
companies_neuron23 -->|"includes"| companies_neuron23_1
style companies_neuron23_1 fill:#ef5350,stroke:#333,color:#000
companies_neuron23_2["Drug Pipeline"]
companies_neuron23 -->|"includes"| companies_neuron23_2
style companies_neuron23_2 fill:#ffd54f,stroke:#333,color:#000
companies_neuron23_3["NEU-411 LRRK2 Inhibitor"]
companies_neuron23 -->|"includes"| companies_neuron23_3
style companies_neuron23_3 fill:#ce93d8,stroke:#333,color:#000
companies_neuron23_4["N23-002 GBA Program"]
companies_neuron23 -->|"includes"| companies_neuron23_4
style companies_neuron23_4 fill:#4fc3f7,stroke:#333,color:#000
companies_neuron23_5["Technology Platform"]
companies_neuron23 -->|"includes"| companies_neuron23_5
style companies_neuron23_5 fill:#81c784,stroke:#333,color:#000
...Overview
Mermaid diagram (expand to render)
Neuron23 Inc. is a clinical-stage biotechnology company headquartered at 343 Oyster Point Blvd, Suite 120, South San Francisco, California 94080, focused on developing precision medicines for genetically defined neurological and immunological diseases. Founded in 2020, the company combines cutting-edge data science, human genetics, and innovative clinical approaches to address the underlying causes of neurodegenerative diseases rather than just treating symptoms["1"].
The company raised a $96.5 million Series D financing in June 2025, providing substantial runway for the NEULARK Phase 2 trial and pipeline expansion [2].
Leadership
The company is led by a team with proven success in both science and business, leveraging expertise in genomics, artificial intelligence, and drug discovery to advance precision medicine for neurological diseases. The leadership includes industry veterans from companies such as Genentech, Biogen, and Google-backed healthcare ventures.
Focus Areas
Neuron23's research focuses on:
- Genetic subtypes of Parkinson's disease: Targeting specific genetic mutations including [LRRK2](/genes/lrrk2), [GBA](/genes/gba), and others [7][8]. The company uses genetic testing to identify patients most likely to benefit from targeted therapies.
- Precision medicine: Developing therapies for patients with specific genetic markers, moving beyond the "one-size-fits-all" approach that has limited success in neurodegenerative disease.
- Neuroimmunology: Exploring the role of tyrosine kinase 2 (TYK2) in neuroimmunology, with research published in PNAS in March 2025 [3][4].
- Novel drug delivery: Enhancing brain penetration for improved efficacy through proprietary medicinal chemistry approaches.
Drug Pipeline
| Drug Candidate | Target | Indication | Development Phase |
|----------------|--------|------------|-------------------|
| NEU-411 | LRRK2 (Leucine-Rich Repeat Kinase 2) | Parkinson's disease | Phase 2 (NEULARK trial) |
| N23-002 | GBA (Glucocerebrosidase) | Parkinson's disease | Preclinical |
NEU-411 (LRRK2 Inhibitor)
NEU-411 is a brain-penetrant, potent, and selective [LRRK2](/genes/lrrk2) kinase inhibitor designed to treat LRRK2-driven [Parkinson's disease](/diseases/parkinsons-disease) — a genetically defined subset of the condition. [LRRK2](/genes/lrrk2) mutations are among the most common genetic causes of familial PD, particularly the G2019S variant which accounts for approximately 5-10% of all PD cases[@lrrk2_review].
Mechanism: NEU-411 is an ATP-competitive inhibitor of LRRK2 kinase activity. It reduces phosphorylation of LRRK2 substrates including Rab GTPases (Rab3, Rab8, Rab10, Rab12), thereby normalizing the vesicular trafficking, autophagy, and lysosomal function that are disrupted by pathogenic LRRK2 mutations.
Clinical Development:
- Phase 1: Healthy volunteer data presented at AD/PD™ 2025 demonstrated favorable pharmacokinetics and target engagement (pSer935-LRRK2 reduction in PBMCs)[@adpd2025]
- Phase 2: NEULARK trial (NCT06436589) — global Phase 2 evaluating NEU-411 in early-stage PD patients with confirmed LRRK2 mutations
- First patient dosed: June 2025[@neuron23_seriesd]
- Primary endpoint: Change from baseline in MDS-UPDRS Part III (motor) score at 52 weeks
- Topline data anticipated: 2027
Competitive Position: NEU-411 competes with BIIB122 (Biogen/Denali, Phase 2b LUMA trial) and G007-LK (Vanqua Bio/Genentech, preclinical). Neuron23 differentiates through its precision medicine approach — exclusively enrolling LRRK2 mutation carriers — and its novel chemical scaffold with favorable selectivity profiles.
For a comprehensive overview, see [LRRK2 Inhibitors for Parkinson's Disease](/therapeutics/lrrk2-inhibitors-parkinsons) and [LRRK2 Kinase Pathway in Parkinson's Disease](/mechanisms/lrrk2-kinase-pathway-parkinsons).
N23-002 (GBA Program)
Neuron23's GBA program targets patients with [glucocerebrosidase](/genes/gba) (GBA) mutations, which are among the most significant genetic risk factors for Parkinson's disease. GBA mutations are found in approximately 5-15% of sporadic PD cases and up to 40% of certain ethnic populations [8]. The N23-002 program is in preclinical development.
Neuron23 employs several key technologies:
- AI-driven target identification: Using machine learning to identify novel therapeutic targets based on human genetic data
- Structure-based drug design: Optimizing drug candidates for potency, selectivity, and brain penetration
- Advanced genomics for patient selection: Identifying patients with specific genetic markers who are most likely to respond to targeted therapies
- Brain-penetrant small molecules: Developing compounds that can cross the [blood-brain barrier](/entities/blood-brain-barrier) while maintaining target engagement
Funding
In June 2025, Neuron23 announced the closing of a $96.5 million Series D financing, providing substantial runway for clinical development and pipeline expansion [2]. Previous funding rounds include:
- Series C: $55 million (2023)
- Series B: $30 million (2021)
- Seed/A: $12 million (2020)
Clinical Trials
| Trial Name | Phase | Indication | Status | NCT Number |
|------------|-------|------------|--------|------------|
| NEULARK | Phase 2 | Early Parkinson's disease (LRRK2+) | Recruiting | NCT06436589 |
Scientific Publications
- Neuron23 research team published on TYK2 in neuroimmunology in PNAS (2025) [4]
- Phase 1 healthy volunteer data presented at AD/PD™ 2025 [5]
- Multiple peer-reviewed publications on LRRK2 biology and drug discovery [7]
Partnerships and Collaborations
Neuron23 maintains collaborations with leading academic institutions and research organizations to advance their precision medicine approach for Parkinson's disease, including partnerships with:
- University of California, San Francisco (UCSF)
- Michael J. Fox Foundation for Parkinson's Research
- Parkinson's Progression Markers Initiative (PPMI)
Career Opportunities
The company maintains a page for current career opportunities, seeking talented individuals with expertise in drug discovery, neuroscience, and bioinformatics.
See Also
- [Parkinson's Disease](/diseases/parkinsons-disease)
- [LRRK2 Gene](/genes/lrrk2)
- [GBA Gene](/genes/gba)
- [Parkinson's Disease Genetics](/diseases/parkinsons-disease#genetic-factors)
- [Alpha-Synuclein](/proteins/alpha-synuclein)
External Links
- [Neuron23 Website](https://www.neuron23.com/)
- [ClinicalTrials.gov](https://clinicaltrials.gov)
- [AD/PD 2025 Conference](https://www.adpd.ionmedevents.com)
References
[Neuron23 Official Website](https://www.neuron23.com)
[Neuron23 Secures $96.5M Series D for LRRK2 Program (2025)](https://neuron23.com/news/series-d-2025)
[AD/PD 2025 International Conference](https://www.adpd.ionmedevents.com)
[Neuron23 Research Team, TYK2 in Neuroimmunology: A Novel Target in CNS Disorders (2025)](https://www.pnas.org)
[Phase 1 Data Presentation at AD/PD 2025](https://www.adpd.ionmedevents.com)
[Alessi DR et al, LRRK2 and Parkinson's Disease: From Genetics to Therapy (2023)](https://pubmed.ncbi.nlm.nih.gov/37831789/)
[Sidransky E et al, GBA Mutations and Parkinson Disease (2020)](https://pubmed.ncbi.nlm.nih.gov/32839561/)